Being specific about race-specific medicine.
Gary Puckrein's paper "BiDil: From Another Vantage Point" misrepresents rather than refutes our previously published analysis of BiDil. Puckrein claims that if our analysis were to prevail, patients would be denied life-saving therapy. Any reasonable reading of our paper suggests exactly the opposite. Indeed, based on the evidence, we urge doctors to prescribe the generics or BiDil itself as they see fit, but without regard to the race of their patient.
Kahn
Jonathan
J
Hamline University School of Law in St. Paul, Minnesota, USA.
Sankar
Pamela
P
D001741:Black or African American / Q000235:genetics*; D017277:Drug Approval; D004338:Drug Combinations; D004345:Drug Industry; D020022:Genetic Predisposition to Disease / Q000208:ethnology; D006333:Heart Failure / Q000188:drug therapy* / Q000208:ethnology; D006801:Humans; D006830:Hydralazine; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration; D014665:Vasodilator Agents / Q000627:therapeutic use*
D004338:Drug Combinations; D014665:Vasodilator Agents; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate